건강한 한국인 자원자에서 말레인산 이르소글라딘의 약동학적 특성에 관한 연구

Pharmacokinetics of Irsogladin Maleate in Healthy Korean Volunteers

  • 이승환 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 임경수 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 김정렬 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 김재우 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 김보형 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 조주연 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 윤서현 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 신상구 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 장인진 (서울대학교 의과대학 및 서울대학교병원임상약리학과) ;
  • 유경상 (서울대학교 의과대학 및 서울대학교병원임상약리학과)
  • Lee, Seung-Hwan (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Lim, Kyoung-Soo (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Kim, Jeong-Ryeol (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Kim, Jae-Woo (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Kim, Bo-Hyung (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Cho, Joo-Youn (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Yoon, Seo-Hyun (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Shin, Sang-Goo (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Jang, In-Jin (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital) ;
  • Yu, Kyung-Sang (Department of Pharmacology, Seoul National University College of Medicine Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital)
  • 투고 : 2008.12.16
  • 심사 : 2009.05.18
  • 발행 : 2009.06.30

초록

Background: Irsogladin maleate, increasing gastric mucosal blood flow and cAMP in mucosal epithelial cells, is being marketed for the treatment of gastric ulcer and gastritis. The object of this study was to evaluate the pharmacokinetic characteristics and safety profiles of irsogladin maleate in Koreans. Methods: An open-label, dose-escalation, parallel group study was conducted in 28 healthy male Korean volunteers. Irsogladin maleate was administered as a single dose of 4 mg (n=16), 8 mg (n=6) or 16 mg (n=6). Serial blood samples for pharmacokinetic analysis were taken over 504 h. Plasma concentration of irsogladin was measured by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were determined using noncompartmental methods. Laboratory tests, ECGs, vital signs and physical examinations were performed for clinical safety evaluation. Results: Maximum observed irsogladin plasma concentration ($C_{max}$) (mean $\pm$ SD) of 4 mg, 8 mg and 16 mg dosage group were $82.9\;{\pm}\;12.5{\mu}\;g/L$, $161.4\;{\pm}\;25.9\;{\mu}g/L$ and $292.6\;{\pm}\;51.2\;{\mu}g/L$, respectively. Area under the plasma concentration versus time curve from dosing to the last quantifiable concentration ($AUC_{last}$) of three dosage groups were $12694.4\;{\pm}2906.2\;{\mu}g\;{\ast}h/L$, $24970.0\;{\pm}\;5253.8\;{\mu}g\;{\ask}h/L$,$47125.3\;{\pm}\;8676.7\;{\mu}g\;{\ast}h/L$, respectively. Apparent clearance ($0.30\;{\pm}\;0.07L/H$, $0.31\;{\pm}\;0.10\;L/H$, $0.31\;{\pm}\;0.06\;L/H$, respectively) was unaffected by dosage. The 95% CI of slope of Dose-$C_max$ and Dose-$AUC_{last}$ linear regression were 15.4-19.6 and 2485.2-3262.0. All adverse events reported were mild and no clinically significant abnormalities of safety evaluation were observed. Conclusions: The pharmacokinetic characteristics of Irsogladin maleate after single dose dministration was explored in healthy Korean volunteers. Irsogladin maleate displayed linear plasma pharmacokinetics over the dose range 4-16 mg. Irsogladin maleate was well tolerated after single dose administration in Koreans.

키워드

참고문헌

  1. Ueda, F., et al., Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung, 1984. 34(4): p. 474-7.
  2. Zhang, X., et al., Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol, 2008. 14(30): p. 4784-90. https://doi.org/10.3748/wjg.14.4784
  3. Kyoi, T., et al., Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci, 2004. 76(1): p. 71-83. https://doi.org/10.1016/j.lfs.2004.06.016
  4. Yao, J., et al., Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis. Br J Pharmacol, 2007. 151(4): p. 457-66. https://doi.org/10.1038/sj.bjp.0707255
  5. Ueda, F., et al., Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric mucosal blood flow in dogs. Arzneimittelforschung, 1984. 34(4): p. 485-91.
  6. Ando, T., K. Momota, and M. Sugiyama, Absorption, distribution and excretion of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate in rats, dogs and monkeys. Arzneimittelforschung, 1986. 36(8): p. 1221-8.
  7. Nakashima, M., et al., Phase I study of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695), a new anti-ulcer agent. Arzneimittelforschung, 1984. 34(4): p. 492-8.
  8. Miyoshi, A., et al., Clinical Evaluation of MN-1695 (Irosgladine maleate) in the Treatment of Gastriris-Multicenter, Doubleblind study in comparison with Cetraxate HCl. 臨床醫藥, 1993. 9(2): p. 357-85.
  9. Miyoshi, A., et al., Clinical evaluation of a novel anti-ulcer agent MN-1695 in gastric ulcer-A multi-center, double blind study in comparison with Cetraxate HCl. 消化器科 (Digestive Medicine), 1986. 5(1): p. 100-20.
  10. 日本新藥株式會社中央硏究所, MN-1695 2m錠, 4mg錠及び0.8%細粒の生物學的同等性試驗に関する資料.
  11. Ethnic factors in the acceptability of foreign clinical data E5, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Current Step 4 version, 1998.
  12. 가교자료평가가이드라인, 식품의약품안전청, 2008.